Comparative Pharmacology
Head-to-head clinical analysis: PULMOLITE versus SODIUM FLUORIDE F 18.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PULMOLITE versus SODIUM FLUORIDE F 18.
PULMOLITE vs SODIUM FLUORIDE F-18
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PULMOLITE is a leukotriene receptor antagonist (LTRA) that selectively and competitively inhibits the cysteinyl leukotriene (CysLT1) receptor in the human airway, thereby reducing bronchoconstriction, mucus secretion, and eosinophilic infiltration.
Positron-emitting radionuclide used for bone imaging; fluoride ion is incorporated into bone matrix via chemisorption onto hydroxyapatite crystals, reflecting blood flow and osteoblastic activity.
Adults: 200 mg intravenously every 12 hours over 30 minutes.
2-10 mCi (74-370 MBq) intravenous bolus injection, single dose for positron emission tomography (PET) bone imaging.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10–14 h) in adults with normal renal function (CrCl >90 mL/min); prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min).
The terminal elimination half-life is approximately 2-4 hours. Clinically, this allows for imaging within 1-3 hours post-injection.
Primarily renal (80%) as unchanged drug; 15% fecal via biliary excretion; 5% metabolized.
Renal (primarily). Approximately 70% of the administered dose is excreted unchanged in urine within 24 hours. Less than 10% is excreted in feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical